Advertisements


Will Positive Phase III Data For Roche"s Anti IL-6 Antibody Spell Trouble For Alexion"s C5 Inhibitor In NMOSD?

Will Positive Phase III Data For Roche"s Anti IL-6 Antibody Spell Trouble For Alexion"s C5 Inhibitor In NMOSD?.....»»

Category: topSource: seekingalphaJan 11th, 2019

Alexion announces positive Phase 3 extension data for ULTOMIRIS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 14th, 2019

Alexion: NEJM publishes "positive" Phase 3 PREVENT data for SOLIRIS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 3rd, 2019

Roche (RHHBY) Announces Positive Data on Hemophilia Drug

Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio. Roche RHHBY announced full results from the phase III study, HAVEN 3, evaluating haemo.....»»

Category: dealsSource: nytMay 21st, 2018

resTORbio Spikes Higher Following Positive Phase 2 Data

resTORbio, Inc. (NASDAQ: TORC) announced Wednesday its TORC1 inhibitor treatment demonstrated targeted improvements in a Phase 2a clinical trial. read more.....»»

Category: blogSource: benzingaJul 11th, 2018

Pfizer"s Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study. Pfizer Inc. PFE announced positive top-line data from a phase IIa.....»»

Category: personnelSource: nytSep 17th, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Alexion to present "positive" Phase 3 data for ALXN1210 at ASH meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data

Omeros Corporation (NASDAQ: OMER) shares are seeing buying interest Thursday following a clinical update on its lead human monoclonal antibody OMS721, which is being evaluated for IgA nephropathy. read more.....»»

Category: blogSource: benzingaJan 17th, 2019

Alexion"s (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy

Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria. Want.....»»

Category: worldSource: nytJun 17th, 2019

Concert Pharma"s CTP-692 Positive for Schizophrenia in Phase I

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophre.....»»

Category: dealsSource: nytJun 13th, 2019

Dr. Reddy"s Reports Positive Top-Line Data on Psoriasis Drug

Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate.....»»

Category: worldSource: nytJun 10th, 2019

Novartis (NVS) Reports Positive Phase III Data on Asthma Drug

Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and momet.....»»

Category: dealsSource: nytMay 31st, 2019

Cara Shares Up on Positive Phase III Data for Itchiness Drug

Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus. Want th.....»»

Category: smallbizSource: nytMay 30th, 2019

Cara Therapeutics stock up 12.6% after company announces positive Phase 3 data for itchiness treatment

Shares of Cara Therapeutics Inc., a bio.....»»

Category: topSource: marketwatchMay 29th, 2019

Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies ex.....»»

Category: earningsSource: benzingaMay 24th, 2019

Syndax can trade to $23 on positive Phase 3 data, says Citi

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2019

Theravance Biopharma reports data from Phase 1b study of JAK inhibitor TD-1473

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2019

Rollercoaster ride for Innovate stock on Wall Street Monday

With wind in its sails from a positive data read-out, one Triangle pharmaceutical company is bringing in $8.7 million in another offering to fund a phase 3 trial. In a series of announcements, Raleigh-based Innovate Biopharmaceuticals (Nasdaq: INNT.....»»

Category: topSource: bizjournalsApr 29th, 2019

Cerecor reports "positive" Phase 1 safety data for CERC-801

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2019

Software maker Segment uses data to create a more positive working environment

With Segment rapidly expanding its employee headcount year over year, scaling its company culture of impact and empowerment can be a challenge, said Adriana Roche, the company‚Äôs vice president of people and places. Roche talks about how the company.....»»

Category: topSource: bizjournalsApr 18th, 2019